IONS Q1 2021 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$112M-16.3% YoY

Gross Profit

$109M97.7% margin

Operating Income

-$92M-82.4% margin

Net Income

-$90M-80.5% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

-61.6%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$58M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.6B

Stockholders' Equity

$681M

Cash & Equivalents

$414M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$112M	$133M	-16.3%
Gross Profit	$109M	$131M	-16.7%
Operating Income	-$92M	-$61M	-50.5%
Net Income	-$90M	-$40M	-126.8%

Revenue Segments

Commercial

$84M43%

Spinraza Royalties

$60M31%

Research and Development Revenue Under Collaborative Agreements

$27M14%

Product

$20M10%

Licensing and Other Royalties

$5M2%